8-K: TriSalus Life Sciences Reports Strong Revenue Growth in 2023, Achieves Key Milestones

TriSalus Life Sciences announced a 77% increase in fourth-quarter revenue and a 49% increase in full-year revenue for 2023, alongside significant clinical and regulatory advancements.

Summary

• TriSalus Life Sciences reported a 77% increase in revenue for the fourth quarter of 2023, reaching $5.7 million, and a 49% increase in full-year revenue, totaling $18.5 million.
• The company achieved a gross margin of 90% in Q4 and 86% for the full year, up from 75% and 82% respectively in 2022.
• Operating losses were $14.1 million for the quarter and $54.2 million for the full year, including $7.9 million in non-recurring professional service fees.
• Net losses were $35.5 million for the quarter and $59.0 million for the full year, impacted by non-cash items.
• The company received CMS reimbursement for the TriNav Infusion System via a new HCPCS code, effective January 1, 2024.
• Real-world data demonstrated the TriNav system's effectiveness in treating patients with higher disease burden.
• TriSalus completed enrollment in multiple phase 1 clinical trials with 100 patients and initiated a first-in-man clinical trial for its pancreatic infusion technology.
• The company received 510k clearance for TriNav Large and TriGuide systems, with a market launch planned for the second half of 2024.
• The company has notified the SEC of a late filing for its annual report due to errors in stock-based compensation calculations.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative information. The strong revenue growth, improved gross margins, and clinical progress are positive. However, the operating and net losses, along with the late filing of the annual report, temper the overall sentiment. The company is making good progress but has some financial challenges to overcome.

Positives

• The company experienced significant revenue growth, with a 77% increase in Q4 and 49% for the full year.
• Gross margins improved substantially, reaching 90% in Q4 and 86% for the full year.
• The TriNav Infusion System secured CMS reimbursement, which should drive future adoption.
• Real-world data supports the effectiveness of the TriNav system in treating complex patients.
• The company has made significant progress in clinical trials, completing enrollment in multiple phase 1 studies.
• The 510k clearance for TriNav Large and TriGuide systems expands the company's market reach.
• The company is actively exploring new treatment options, including a novel pancreatic infusion technology.

Negatives

• The company reported operating losses of $14.1 million for Q4 and $54.2 million for the full year.
• Net losses were $35.5 million for Q4 and $59.0 million for the full year, impacted by non-cash items.
• The company has notified the SEC of a late filing for its annual report due to errors in stock-based compensation calculations.
• The company's net losses include the impact of non-cash related gains/(losses) on revaluation of contingent earnout liabilities, tranche and warrant liabilities, and equity issuance.

Risks

• The company's financial results are unaudited and subject to change.
• The company has identified errors in stock-based compensation calculations, which may require corrections to previous financial results.
• Clinical trial results may not be consistent with previous data, impacting the success of product candidates.
• The company faces risks associated with regulatory approval and market competition.
• The company's ability to timely file its Annual Report on Form 10-K is at risk.
• The company's future success depends on the successful development and commercialization of its products.

Future Outlook

The company plans to analyze data from completed phase 1 clinical trials in the second half of 2024, launch TriNav Large and TriGuide systems in the second half of 2024, and complete enrollment and report data from the phase 1 study of its pancreatic infusion device in the second half of 2024. The company also intends to file a Form 12b-25, Notice of Late Filing, with the SEC.

Management Comments

• 2023 was a critical year for TriSalus, underscored by significant growth in TriNav revenue, a landmark achievement of permanent reimbursement, and disciplined progress within our technology and clinical pipelines, said Mary Szela, Chief Executive Officer and President of TriSalus.
• The release of compelling real-world evidence demonstrating the impactful benefits of the TriNav method for complex patients, along with the exploration of nelitolimod in conjunction with the TriNav system through selected phase 1 clinical studies, reinforces our commitment to improving care options for oncology patients.
• Furthermore, receiving 510k clearance of a larger vessel size of the TriNav system, and successfully accessing the public markets underscore our dedication to advancing our company for sustained growth and success.
• As we reflect on the achievement of the past year, we recognize not only the milestones achieved but also acknowledge the solid foundation for continued future progress across the business, and we remain fully focused and committed to delivering benefit to patients.

Industry Context

This announcement highlights TriSalus's progress in the oncology space, particularly in the treatment of liver and pancreatic tumors. The company's focus on novel drug delivery technologies and immunotherapies positions it to potentially disrupt the market. The CMS reimbursement for the TriNav system is a significant step towards broader adoption and market penetration. The company's focus on difficult to treat cancers such as pancreatic cancer is a key differentiator.

Comparison to Industry Standards

• TriSalus's 77% Q4 revenue growth and 49% full-year growth significantly outpaces many established medical device companies, which typically see single-digit or low double-digit growth rates.
• The 90% gross margin in Q4 is exceptionally high for a medical device company, suggesting strong pricing power and efficient manufacturing processes. Companies like Intuitive Surgical (ISRG) and Medtronic (MDT) typically have gross margins in the 60-70% range.
• The successful completion of enrollment in multiple phase 1 clinical trials and the initiation of a first-in-man trial for the pancreatic infusion technology demonstrate a strong commitment to innovation, comparable to companies like BioNTech (BNTX) and Moderna (MRNA) in their early stages of development.
• The 510k clearance for TriNav Large and TriGuide systems is a key regulatory milestone, similar to what companies like Boston Scientific (BSX) and Abbott (ABT) achieve with their new product launches.
• The company's focus on targeted drug delivery for liver and pancreatic tumors is a niche area, but the real-world data demonstrating the TriNav system's effectiveness in treating patients with higher disease burden is a significant differentiator compared to standard catheter-based treatments.

Stakeholder Impact

• Shareholders may be encouraged by the strong revenue growth and clinical progress, but concerned about the losses and late filing.
• Employees may be motivated by the company's achievements but concerned about the financial challenges.
• Customers (hospitals and physicians) may be more likely to adopt the TriNav system due to the CMS reimbursement and positive real-world data.
• Suppliers may see increased demand for the company's products.
• Creditors may be concerned about the company's losses but reassured by the revenue growth and clinical progress.

Next Steps

• The company will analyze data from completed phase 1 clinical trials in the second half of 2024.
• TriNav Large and TriGuide systems will be launched in the second half of 2024.
• The company will complete enrollment and report data from the phase 1 study of its pancreatic infusion device in the second half of 2024.
• The company will file its Annual Report on Form 10-K after addressing the errors in stock-based compensation calculations.

Key Dates

Keywords

TriNav Infusion System, Pancreatic Infusion System, PEDD, nelitolimod, liver cancer, pancreatic cancer, immunotherapy, clinical trials, CMS reimbursement, 510k clearance, revenue growth, gross margin